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Abstract 
Breast conserving therapy (BCT) for breast cancer aims to achieve long-term local disease 
control with reduced local morbidity. BCT has similar long-term survival outcomes to 
mastectomy in patients with early breast cancer and recent studies have reported similar rates 
of recurrence compared with mastectomy. An increasing number of studies have shown 
improved overall survival among women treated with BCT regardless of cancer phenotype 
compared with mastectomy. Despite BCT being at least equivalent in outcome to mastectomy 
many women with small breast cancers continue to be treated by mastectomy and several 
studies in the last decade have shown a trend of increasing numbers of unilateral and bilateral 
mastectomies. The advent of increasingly effective neoadjuvant treatment has allowed even 
more women to have breast conservation. Not only has neoadjuvant therapy been shown to 
increase the rates of BCT, it does so without increasing in breast recurrence rates. Patients 
who are suitable for BCT should be advised that BCT is the best treatment option for them. 
They should be informed that not only does it confer at least equivalent survival and local 
recurrence rates but that compared with mastectomy it has the advantages of less 
complications, better quality of life and many less operations if reconstructive surgery is 
performed. It may no longer be appropriate to offer women suitable for BCT the choice of 
mastectomy or BCT.  
 
 
 
 
 
 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Introduction 
 
Breast conserving therapy (BCT) consists of breast conserving surgery and whole breast 
radiotherapy and aims to achieve long-term local disease control with minimum local 
morbidity. Almost two thirds of screen detected cancers and the majority of women 
presenting to symptomatic breast clinics have early breast cancers that are suitable for BCT. 
There are a number of advantages of BCT for women with early breast cancer who do not 
have a genetic mutation predisposing to breast cancer. For the majority BCT produces an 
acceptable cosmetic result (1) and is associated with lower levels of psychological morbidity, 
notably less anxiety and depression and improved body image, sexuality and self-esteem, 
compared with mastectomy (2, 3). Two systematic reviews performed many years ago 
showed equivalence in terms of disease outcome for BCT and mastectomy (4, 5). Local 
control is important and has an influence on overall survival with local failure being a risk 
factor for the development of metastatic disease (6, 7). An initial review of 6 randomised 
trials noted similar rates of local recurrence comparing BCT and mastectomy and even in 
1997 it was evident to the authors that ”particularly for node-positive patients, BCT may 
confer a relative survival advantage over mastectomy. In particular, mastectomy without 
adjuvant radiation appears to be inferior to BCT for node-positive patients” (5). A subsequent 
analysis did report a higher locoregional recurrence rate for BCT in 4 of the 6 trials (8). Local 
recurrence rates following BCT have fallen over time as a result of better imaging, more 
attention to margins, and more effective and longer durations of systemic therapy so that 
although local recurrence was at one time considered more common after BCT than 
mastectomy, this no longer appears true (9). Current practice is to aim for at least 
microscopically disease-free margins. There is ongoing debate about how much breast tissue 
should be removed and what constitutes a clear margin. A meta-analysis of 33 studies 
showed that positive margins conferred an odds ratio of ipsilateral breast tumour recurrence 
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of 2.44 and close margins had an odds ratio of 1.74, which were both significant compared to 
negative margins (10). When looking at different threshold for negative margins 1mm was as 
good as wider margins. The data on >0mm were insufficient and there were minimal data on 
this margin included in the meta-analysis (10). For this reason the most commonly used 
negative margin in the UK is 1mm. What is clear from the meta-analysis is that wider 
margins will not reduce local recurrence but wider margins impact negatively on cosmetic 
outcome. 
 
The rates of in breast tumour recurrence are now very similar to the rates of local recurrence 
seen after mastectomy alone even in young women (11). Although young age at diagnosis is 
associated with increased rates of in breast tumour events in part because young women have 
higher grade and triple negative cancers these same women and cancer types are associated 
with an increased rate of recurrence after mastectomy. A recent review showed equivalence 
between BCT and mastectomy in local regional control in young women (11).  
 
The decision to have mastectomy has been based first on the belief that mastectomy 
decreases local recurrence rates compared with BCT and second because of the fear of annual 
mammograms and recall for further treatment. Given that recurrence rates are the same, recall 
rates after BCT are now very low and with newer studies showing improved survival for 
BCT the aim of this review is to detail what is known about the outcomes of these two 
surgical approaches and to answer the question, whether there is any specific group of 
women where BCT is not a better option than mastectomy?  
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Comparing survival with BCT and Mastectomy 
Although randomised controlled trials comparing BCT with mastectomy performed many 
years ago for early stage breast cancer showed equivalence in overall survival (12-17), and 
recurrence rates after BCT have fallen dramatically since these randomised trials both for 
mastectomy and in particular for BCT (9), there continues to be a high and increasing 
mastectomy rate (18). One potential reason for this increase has been the increasing use of 
MRI (19, 20), although, in the USA there are other reasons why there has also been an 
increase in mastectomies for both women with invasive and in situ disease (18). One reason 
for this increase is improvements in reconstructive techniques, and a reported reduction in 
anxiety of long term follow-up after mastectomy because of a perceived lower rate of 
recurrence and the avoidance of follow up mammography. The evidence of higher local 
recurrence rates following BCT in patients with certain tumour phenotypes has added to this 
(21, 22). Recurrence rates in these women are however also increased to a similar degree 
after mastectomy (23). Using tumour phenotype to decide surgery is not therefore supported 
by evidence. 
 
A number of recent studies have cast doubt on the equivalence in outcomes of mastectomy 
and BCT and have raised the issue of whether women with early breast cancer suitable for 
BCT should any longer be offered the choice of mastectomy or BCT. A series of studies from 
various different countries have reported outcomes related to the type of surgery performed 
including breast cancer specific and overall survival in women with stage I–II breast cancer. 
The aim of these studies was to determine the influence of surgery type on long-term 
outcomes for early stage disease (24). One large cohort study from California consisted of 
112,154 women, of whom 61,771 (55%) were treated by BCT and 50,383 (45%) by 
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mastectomy without radiation. At a median follow up time of 110.6 months, women 
undergoing BCT had a significantly improved overall (HR = 0.81, 95% CI 0.80-0.83) and 
breast cancer disease specific survival (HR = 0.85, 95% CI 0.78-0.91) when compared to 
women treated with mastectomy. The disease specific survival benefit for BCT compared to 
mastectomy was somewhat greater among women age ≥ 50 with HR-positive disease (HR 
=0.86, 95% CI 0.82-0.91) than among women age <50 with HR-negative disease (HR = 0.88, 
95% CI 0.79-0.98); although the benefit of BCT was significant in all ages and subgroups 
analysed. This study concluded that in patients with early stage breast cancer, BCT resulted 
in significantly improved disease specific survival compared with mastectomy. These data 
provide confidence that BCT is an effective alternative to mastectomy for early stage disease 
regardless of age, HR status and cancer phenotype (24). The better outcomes for BCT 
persisted  after adjusting for tumour grade, proportion of positive nodes, race, socioeconomic 
status, tumour size, age at diagnosis, and year of diagnosis (24). A number of other recent 
studies have provided supportive evidence of better outcomes for BCT compared to 
mastectomy. In a population based study from the Netherlands, in women treated between 
2006 and 2012, BCT conferred a survival advantage in a group of 173,797 patients compared 
with mastectomy following correction for stage, age, and adjuvant therapies (HR 0.87 95% 
CI 0.81-0.93 p<.001) (25). A further study conducted in Norway included 9547 women aged 
50-69 years diagnosed with primary invasive breast cancer without distant metastasis, who 
underwent either BCT or mastectomy between 2005 and 2011. Women treated with BCT had 
more favourable tumour characteristics compared to women treated with mastectomy. 
Adjusted analyses revealed a 1.7 (95% CI 1.3-2.4) greater risk of breast cancer death amongst 
women who underwent mastectomy compared with BCT (26). This study showed a better 
survival from BCT in screen detected, interval and symptomatic cancers. A second 
Norwegian study of 13,015 women with invasive, early-stage breast cancer treated over a ten 
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year period when the outcomes for BCT and mastectomy were considered to be equal (27). 
BCT and mastectomy was compared in five subcohorts. Analyses were stratified into 
T1N0M0, T2N0M0, T1N1M0, T2N1M0, and age groups (<50, 50–69, ≥70). Women who 
underwent mastectomy had a hazard ratio of 1.64 (95% CI 1.43-1.88) for breast cancer death 
compared with women who underwent BCT after adjusting for the year of diagnosis, age at 
diagnosis, stage, histology, and grade. Outcome was better for BCT in all 5 cohorts. The 
authors concluded that survival was better or at least equivalent for BCT compared with 
mastectomy in all stages, surgical subcohorts, and age groups. Any advantage in outcome 
could not be attributed to differences in tumour biology (27). A US study investigated 
132,149 patients treated over a ten year period from the SEER database, BCT was used to 
treat 70% of patients, mastectomy alone was used to treat 27% of patients, and mastectomy 
with radiation was used in 3% of patients. The 5-year breast cancer-specific survival rates for 
patients who underwent BCT, mastectomy alone, or mastectomy with radiation were 97%, 
94%, and 90%, (P < .001); the 10-year breast cancer-specific survival rates were 94%, 90%, 
and 83%, respectively (P < .001). Multivariate analysis showed that women undergoing BCT 
had a significantly better survival rate compared to those undergoing mastectomy alone 
(hazard ratio, 1.31; 95% CI 1.25-1.39 P < .001) or mastectomy with radiation (hazard ratio, 
1.47; 95% CI 1.34-1.61 P < .001). When stratified using propensity score, the effect of 
treatment on survival remained largely unchanged (28). The most recent study from the 
Netherlands presented at San Antonio also reported significantly better overall survival for 
BCT compared with mastectomy (HR=0.79 95% CI 0.75-0.83) (29). 
 
Findings have also been reported for specific breast cancer subtypes. In a study of 1242 
consecutive patients with triple negative breast cancer treated over ten years at a single 
institution, the 5-year risk of locoregional recurrence was 4.7 % in women with T1-2N0 
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disease. 448 of this cohort with T1, T2N0 cancer had BCT, and 198 had Mastectomy but no 
radiotherapy. BCT was as effective as mastectomy both for local and distant control (30). In 
another study of T1-2N0 triple negative breast cancers, women treated by mastectomy 
without radiotherapy had a significantly increased risk of locoregional recurrence compared 
with those treated with BCT (31). A series of studies have included data on women with 
triple negative breast cancers and these were combined in a meta-analysis presented at San 
Antonio in 2015. In the total cohort there were 37,207 patients. The 10-year OS was 76.8% 
after BCT and 59.7% after mastectomy. In a sub cohort, 11.0% of the patients experienced 
distant metastases (DM) after BCT compared to 14.7% after mastectomy (p<0.001). Regional 
recurrences (RR) were diagnosed in 2.1% of patients treated with BCT and in 4.0% of 
patients treated with mastectomy (p<0.001).  The percentage who developed local 
recurrences (LR) did not differ between treatment groups (29). Overall the rate of 
locoregional recurrence was 39% less with BCT (HR = 0.61, 95% CI 0.41-0.90) and overall 
survival was 43% better with BCT (HR = 0.57, 95% CI 0.31-1.02 p=0.012). The conclusion 
of this analysis was that for women with triple negative breast cancer who are not gene 
mutation carriers, BCT appears a better option than mastectomy.  
There is thus an increasing number of studies that have suggested that women treated with 
BCT may have a better breast cancer-specific survival and a lower risk of dying from breast 
cancer than women treated with mastectomy, independent of tumour characteristics. These 
reports importantly include all cancer phenotypes. They are in the main observational studies 
and some of the difference in outcomes is likely to be due to selection bias, however in the 
US studies many patients with small low risk cancers choose mastectomy, so it is difficult to 
explain the differences in outcome based purely on mastectomy patients having higher risk 
disease. 
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Not only are there potential survival advantages for BCT compared with mastectomy, but the 
rate of surgical complications and economic burden particularly with brachytherapy is better 
for BCT (32). Mastectomy has twice the rate of complications compared with BCT, and is a 
much less cost effective option than BCT particularly when mastectomy is combined with 
breast reconstruction. Another advantage of BCT is that it may allow patients to avoid 
axillary dissection if they are node positive on sentinel node biopsy and fulfil the ACOSOG 
Z-0011 criteria. After BCT ACOZOG Z-0011 showed that patients with 1 or 2 positive 
sentinel nodes do not get either a reduction in locoregional recurrence or a survival advantage 
by having an axillary node dissection (33).  
 
Can BCT rates be increased even further with Neoadjuvant Therapy? 
A major benefit of neo-adjuvant chemotherapy is its potential to increase the rate of breast 
conservation, a procedure known to be associated with less morbidity and improved body 
image compared with complete breast removal (34). A systematic review and meta-analysis 
considered fourteen studies that randomised 5500 women (35). This review demonstrated that 
neoadjuvant chemotherapy results in survival rates at least equivalent to those associated with 
adjuvant chemotherapy. In the neoadjuvant group, the mastectomy rate was lower (relative 
risk 0·71) and when BCT was performed, this was without a significant increase in local 
recurrence (hazard ratio 1·12). Importantly there were significantly less infective episodes 
with neoadjuvant compared with adjuvant chemotherapy and there was no increase in 
surgical complications with NAC (35). Performing mastectomy with reconstruction, can 
delay chemotherapy in some patients, and delay has been reported in at least 3 major series 
that have investigated whether breast reconstruction delays adjuvant chemotherapy (36). In 
patients considering mastectomy and reconstruction, giving chemotherapy first has the 
advantage of allowing consideration of options and planning surgery if a complex 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
reconstruction is to be performed. Neoadjuvant endocrine therapy has also been shown to 
increase the rates of BCT without increasing local recurrence (37).  
 
Are there any contraindications to BCT? 
Multifocal or multicentric cancers have been considered a contraindication to BCT but this is 
based on a small number of patients in a small number of observational studies performed 
over 2 decades ago. An emerging body of evidence indicates BCT is a viable for many such 
patients. Acceptable local recurrence rates can be obtained providing that all margins of 
excision are clear of disease independent of the number of cancers in the breast (38). One 
recent study involving 19000 women compared local recurrence rates after mastectomy or 
breast-conserving surgery for multifocal/multicentric versus unifocal breast cancer, and in the 
multivariate analysis, although there was an increased risk of local relapse in the 
multifocal/multicentric group in the mastectomy group, this was not observed in the BCT 
group (39). BCT is also an option for patients with central cancers and large areas (>4cm) of 
DCIS when combined with a therapeutic mammoplasty (40) 
 
Mastectomy a poor operation 
One issue with mastectomy is that it does not remove all breast tissue. In a series of 206 
women who underwent mastectomy biopsy samples were taken from skin flaps. In 76.2 % of 
the specimens, one or more biopsy samples showed breast tissue was present. The findings of 
breast tissue on mastectomy flaps were found diffusely across the superficial dissection 
surface of the specimen (41).  
Whole breast radiotherapy treats all the skin and lymphatics under the skin whereas in 
mastectomy patients who do not have chest wall radiation any disease in lymphatics is 
targeted only by the systemic therapy. Not only does a mastectomy leave breast tissue behind 
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but it can have major psychological effects on women. One quality of life study performed in 
990 women compared long-term quality of life between breast cancer patients treated by 
BCT or mastectomy. Mastectomy patients had significantly lower body image, and sexual 
functioning scores and their lives were more disrupted than BCT patients. Emotional and 
social functioning and financial and future health worries were significantly worse for 
younger patients after mastectomy. Patients ≥70 years of age also reported higher body image 
and lifestyle scores when treated with BCT (42). What is not widely appreciated is that 
patients undergoing mastectomy and axillary dissection have a significantly higher rate of 
lymphoedema compared with patients having BCT (RR=1.42; 95% CI 1.15-1.76)  (43). 
Chronic pain is also much more common after mastectomy than BCT and is a particular issue 
in women undergoing a contralateral prophylactic mastectomy (44).  
 
Conclusions 
The proponents of a more consumerist approach to healthcare assert the positive benefits of 
active participation in treatment decision making BUT any benefits of patient involvement in 
choosing treatment are not well supported by firm data (45). Giving patients a choice of 
treatments indicates that the two choices are equal. Increasing evidence indicates that BCT is 
a superior option for patients with early operable breast cancer and that patients treated by 
BCT have better outcomes. BCT is associated with survival which is at least as good, and 
from recent studies may be better than mastectomy and patients can keep their own breast 
with intact sensation, which results in less morbidity and less surgical complications, all of 
which ultimately leads to a potentially better quality of life. It no longer seems logical to offer 
all patients with early breast cancer, who are not gene carriers, the option of BCT or 
mastectomy. Such patients should be advised that BCT is their optimal treatment. Any peace 
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of mind that patients report after mastectomy is not based on evidence and BCT appears 
optimal treatment for most women with early breast cancer.  
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